TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02513550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ
Study: NCT00192114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin HCl
Description: 1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
Study: NCT00217490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary counseling via computer
Description: An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary counseling via nutritionist
Description: A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined computer and nutritionist
Description: An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity counseling via computer
Description: An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
Study: NCT03356652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive electrical dyssynchrony study
Description: Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations.
Study: NCT00472420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375mg/m2 iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First line chemotherapy
Description: As prescribed
Study: NCT00113607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL
Description: Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
Study: NCT00568971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, 5-Fu
Description: Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
Study: NCT03916588

Intervention type: BEHAVIORAL
Intervention: Individualized Care Plan
Description: Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
Study: NCT04606693

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment of SAHS
Description: Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
Study: NCT04566107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Description: The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Plus
Description: The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
Study: NCT03073928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: Regional Anesthesia procedure in the neck

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracoracoid SPB
Description: Regional anesthesia procedure under the collar bone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
Study: NCT01338896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: 8 mg/24 h, transdermal patch 8 mg/24 h, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: 8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
Study: NCT04071041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Human
Description: Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
Study: NCT01362764

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate suspension Formulation 1
Description: Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate suspension Formulation 2
Description: Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate tablets
Description: Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
Study: NCT03072550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenewalNail™ Plasma Treatment System
Description: application of cold atmospheric plasma to a fungal infected toenail
Study: NCT01064479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01670292

Intervention type: OTHER
Group type: OTHER
Intervention: HVLA-SM
Description: High Velocity Low Amplitude Spinal Manipulation
Study: NCT04420091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cartidyss
Description: Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
Study: NCT02227095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Heart rate monitors worn by each child at each session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-school program
Description: Supervised recreational program with token economy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After-school program
Description: Supervised recreational program with token economy
Study: NCT00471497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Study: NCT00514085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin-21
Description: Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Cycle 1 Day 1 and Cycle 1 Day 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Starting dose of 50μg/kg/day as an IV push
Study: NCT02515435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib single agent
Description: For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
Study: NCT01876524

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Random Noise Stimulation
Description: Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
Study: NCT00706680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
Study: NCT02528448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-lyte
Description: Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,9% saline
Description: Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
Study: NCT01682980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
Study: NCT02679664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg tablet of rosuvastatin
Study: NCT03043456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic complete denture
Description: A device used to substitute the teeth for edentulous patients made of thermoplastic resin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional acrylic resin complete denture
Description: A device used to substitute the teeth for edentulous patients made of acrylic resin
Study: NCT04494646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Once-daily administration of bardoxolone methyl (20mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily administration of matching placebo
Study: NCT00286182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin alpha
Description: Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01746862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saizen®
Description: Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
Study: NCT02276469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer support
Description: peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
Study: NCT02633722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention B
Description: Time limiting feeding from 8-5pm (TRFb)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention D
Description: Time limiting feeding (12-9pm)
Study: NCT03694379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation during endotracheal intubation
Description: Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
Study: NCT02425306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyICLC
Description: polyICLC, local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyICLC
Description: polyICLC, local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, systemic adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, systemic adjuvant
Study: NCT00707837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infant formulas and discharge formulas
Description: Preterm infant formulas to be consumed per health care provider orders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm infant formula with added soluble lipids
Description: Preterm infant formula to be fed per healthcare provider instructions
Study: NCT03261206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-ASA Withdrawal
Description: Withdrawal of 5-ASA therapy
Study: NCT04507152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction resistance training
Description: The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
Study: NCT02423226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography guided radioactive seeds implant
Description: Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy (FOLFIRI)
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (FOLFIRI)
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks